Biomarker Report from the Phase II Lamotrigine Trial in Secondary Progressive MS - Neurofilament as a Surrogate of Disease Progression

PLoS ONE

Volumn 8, Issue 8, 2013, Pages

  Gnanapavan, Sharmilee ^a   Grant, Donna ^a   Morant, Steve ^b   Furby, Julian ^a   Hayton, Tom ^a   Teunissen, Charlotte E ^c   Leoni, Valerio ^d   Marta, Monica ^e   Brenner, Robert ^f   Palace, Jacqueline ^g   Miller, David H ^a   Kapoor, Raj ^a   Giovannoni, Gavin ^e  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b VU University Medical Center Amsterdam ^*

^c VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^d DEPARTMENT OF NEUROSURGERY   (Italy)

^e QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^f ROYAL FREE HOSPITAL   (United Kingdom)

^g RADCLIFFE INFIRMARY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BRAIN DERIVED NEUROTROPHIC FACTOR; GLIAL FIBRILLARY ACIDIC PROTEIN; LAMOTRIGINE; NERVE GROWTH FACTOR; NEUROFILAMENT PROTEIN; NITROGEN OXIDE; OSTEOPONTIN; PLACEBO;

ADULT; ARTICLE; BRAIN ATROPHY; CEREBROSPINAL FLUID ANALYSIS; CONTROLLED STUDY; DISEASE COURSE; DISEASE MARKER; DRUG RESPONSE; HUMAN; MAJOR CLINICAL STUDY; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PHASE 2 CLINICAL TRIAL (TOPIC); PREDICTION; PROGNOSIS; PROTEIN BLOOD LEVEL; PROTEIN DETERMINATION; SCORING SYSTEM;

ATROPHY; BIOLOGICAL MARKERS; BRAIN; CLINICAL TRIALS, PHASE II AS TOPIC; DISEASE PROGRESSION; FEMALE; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; NEUROFILAMENT PROTEINS; PROGNOSIS; SPINAL CORD; TIME FACTORS; TREATMENT OUTCOME; TRIAZINES;

EID: 84880983969     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0070019     Document Type: Article

References (22)

1. Petzold A, Eikelenboom MJ, Keir G, Grant D, Lazeron RH, et al. (2005) Axonal damage accumulates in the progressive phase of multiple sclerosis: three year follow up study. J Neurol Neurosurg Psychiatry 76: 206-211.
2. Shaw G, Yang C, Ellis R, Anderson K, Parker Mickle J, et al. (2005) Hyperphosphorylated neurofilament NF-H is a serum biomarker of axonal injury. Biochem Biophys Res Commun 336: 1268-1277.
3. Kuhle J, Leppert D, Petzold A, Regeniter A, Schindler C, et al. (2011) Neurofilament heavy chain in CSF correlates with relapses and disability in multiple sclerosis. Neurology 76: 1206-1213.
4. Teunissen CE, Iacobaeus E, Khademi M, Brundin L, Norgren N, et al. (2009) Combination of CSF N-acetylaspartate and neurofilaments in multiple sclerosis. Neurology 72: 1322-1329.
5. Petzold A, Brassat D, Mas P, Rejdak K, Keir G, et al. (2004) Treatment response in relation to inflammatory and axonal surrogate marker in multiple sclerosis. Mult Scler 10: 281-283.
6. Kapoor R, Furby J, Hayton T, Smith KJ, Altmann DR, et al. (2010) Lamotrigine for neuroprotection in secondary progressive multiple sclerosis: a randomised, double-blind, placebo-controlled, parallel-group trial. Lancet Neurol 9: 681-688.
7. Rejdak K, Petzold A, Sharpe MA, Smith M, Keir G, et al. (2003) Serum and urine nitrate and nitrite are not reliable indicators of intrathecal nitric oxide production in acute brain injury. J Neurol Sci 208: 1-7.
8. Petzold A, Keir G, Green AJ, Giovannoni G, Thompson EJ, (2004) An ELISA for glial fibrillary acidic protein. J Immunol Methods 287: 169-177.
9. Leoni V, Mariotti C, Tabrizi SJ, Valenza M, Wild EJ, et al. (2008) Plasma 24S-hydroxycholesterol and caudate MRI in pre-manifest and early Huntington's disease. Brain 131: 2851-2859.
10. Kester MI, Scheffer PG, Koel-Simmelink MJ, Twaalfhoven H, Verwey NA, et al. (2012) Serial CSF sampling in Alzheimer's disease: specific versus non-specific markers. Neurobiol Aging 33: 1591-1598.
11. Jasperse B, Jakobs C, Eikelenboom MJ, Dijkstra CD, Uitdehaag BM, et al. (2007) N-acetylaspartic acid in cerebrospinal fluid of multiple sclerosis patients determined by gas-chromatography-mass spectrometry. J Neurol 254: 631-637.
12. Lim ET, Sellebjerg F, Jensen CV, Altmann DR, Grant D, et al. (2005) Acute axonal damage predicts clinical outcome in patients with multiple sclerosis. Mult Scler 11: 532-536.
13. Koyama T, Domen K, Yokoe M, Sakoda S, Kandori A, (2011) Psychometrics of dominant right hand during the 9-hole PEG test: differences between PEG placement and removal. PM R 3: 40-44.
14. Pasol J, Feuer W, Yang C, Shaw G, Kardon R, et al. (2010) Phosphorylated neurofilament heavy chain correlations to visual function, optical coherence tomography, and treatment. Mult Scler Int 2010: 542691.
15. Petzold A, Plant GT, (2011) The diagnostic and prognostic value of neurofilament heavy chain levels in immune-mediated optic neuropathies. Mult Scler Int 2012: 217802.
16. Vercellino M, Masera S, Lorenzatti M, Condello C, Merola A, et al. (2009) Demyelination, inflammation, and neurodegeneration in multiple sclerosis deep gray matter. J Neuropathol Exp Neurol 68: 489-502.
17. McGuigan C, Hutchinson M, (2004) The multiple sclerosis impact scale (MSIS-29) is a reliable and sensitive measure. J Neurol Neurosurg Psychiatry 75: 266-269.
18. Bergers E, Bot JC, De Groot CJ, Polman CH, Lycklama a Nijeholt GJ, et al. (2002) Axonal damage in the spinal cord of MS patients occurs largely independent of T2 MRI lesions. Neurology 59: 1766-1771.
19. Cheriyan J, Kim S, Wolansky LJ, Cook SD, Cadavid D, (2012) Impact of inflammation on brain volume in multiple sclerosis. Arch Neurol 69: 82-88.
20. Moalem G, Gdalyahu A, Shani Y, Otten U, Lazarovici P, et al. (2000) Production of neurotrophins by activated T cells: implications for neuroprotective autoimmunity. J Autoimmun 15: 331-345.
21. Comabella M, Pericot I, Goertsches R, Nos C, Castillo M, et al. (2005) Plasma osteopontin levels in multiple sclerosis. J Neuroimmunol 158: 231-239.
22. Jia Y, Wu T, Jelinek CA, Bielekova B, Chang L, et al. (2012) Development of protein biomarkers in cerebrospinal fluid for secondary progressive multiple sclerosis using selected reaction monitoring mass spectrometry (SRM-MS). Clin Proteomics 9: 9.